Xiaoyi Wang, Jinming Zhao, Xiangdong Wang, Luo Zhang
{"title":"代谢组图谱可预测阻塞性睡眠呼吸暂停低通气综合征患者的临床严重程度。","authors":"Xiaoyi Wang, Jinming Zhao, Xiangdong Wang, Luo Zhang","doi":"10.5664/jcsm.11160","DOIUrl":null,"url":null,"abstract":"<p><strong>Study objectives: </strong>Obstructive sleep apnea-hypopnea syndrome (OSAHS) poses a significant health hazard, intermittent hypoxia inflicts damage throughout the body and is considered a critical risk factor for metabolic disorders. The aim of this study was to establish a metabolic profile for patients with OSAHS using nontargeted metabolomics detection techniques, providing a basis for OSAHS diagnosis and novel biological marker identification.</p><p><strong>Methods: </strong>45 patients with OSAHS composed the OSAHS group, and 44 healthy volunteers composed the control group. Nontargeted metabolomics technology was used to analyze participants' urinary metabolites. Differentially abundant metabolites were screened and correlated through hierarchical clustering analysis. We constructed a composite metabolite diagnostic model using a random forest model. Simultaneously, we analyzed the relationships between 20 metabolites involved in model construction and OSAHS severity.</p><p><strong>Results: </strong>The urinary metabolomics pattern of the OSAHS group exhibited significant changes, demonstrating noticeable differences in metabolic products. Urinary metabolite analysis revealed differences between the mild-to-moderate OSAHS and severe OSAHS groups. The composite metabolite model constructed in this study demonstrated excellent diagnostic performance not only in distinguishing healthy control participants from patients with mild-to-moderate OSAHS (area under the curve = 0.78) and patients with severe OSAHS (area under the curve = 0.78), but also in discriminating between patients with mild-to-moderate and severe OSAHS (area under the curve = 0.71).</p><p><strong>Conclusions: </strong>This study comprehensively analyzed the urinary metabolomic characteristics of patients with OSAHS. The established composite metabolite model provides robust support for OSAHS diagnosis and severity assessment. Twenty metabolites associated with OSAHS disease severity offer a new perspective for diagnosis.</p><p><strong>Citation: </strong>Wang X, Zhao J, Wang X, Zhang L. Metabolomic profiles predict clinical severity in patients with obstructive sleep apnea-hypopnea syndrome. <i>J Clin Sleep Med.</i> 2024;20(9):1445-1453.</p>","PeriodicalId":50233,"journal":{"name":"Journal of Clinical Sleep Medicine","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11367723/pdf/","citationCount":"0","resultStr":"{\"title\":\"Metabolomic profiles predict clinical severity in patients with obstructive sleep apnea-hypopnea syndrome.\",\"authors\":\"Xiaoyi Wang, Jinming Zhao, Xiangdong Wang, Luo Zhang\",\"doi\":\"10.5664/jcsm.11160\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Study objectives: </strong>Obstructive sleep apnea-hypopnea syndrome (OSAHS) poses a significant health hazard, intermittent hypoxia inflicts damage throughout the body and is considered a critical risk factor for metabolic disorders. The aim of this study was to establish a metabolic profile for patients with OSAHS using nontargeted metabolomics detection techniques, providing a basis for OSAHS diagnosis and novel biological marker identification.</p><p><strong>Methods: </strong>45 patients with OSAHS composed the OSAHS group, and 44 healthy volunteers composed the control group. Nontargeted metabolomics technology was used to analyze participants' urinary metabolites. Differentially abundant metabolites were screened and correlated through hierarchical clustering analysis. We constructed a composite metabolite diagnostic model using a random forest model. Simultaneously, we analyzed the relationships between 20 metabolites involved in model construction and OSAHS severity.</p><p><strong>Results: </strong>The urinary metabolomics pattern of the OSAHS group exhibited significant changes, demonstrating noticeable differences in metabolic products. Urinary metabolite analysis revealed differences between the mild-to-moderate OSAHS and severe OSAHS groups. The composite metabolite model constructed in this study demonstrated excellent diagnostic performance not only in distinguishing healthy control participants from patients with mild-to-moderate OSAHS (area under the curve = 0.78) and patients with severe OSAHS (area under the curve = 0.78), but also in discriminating between patients with mild-to-moderate and severe OSAHS (area under the curve = 0.71).</p><p><strong>Conclusions: </strong>This study comprehensively analyzed the urinary metabolomic characteristics of patients with OSAHS. The established composite metabolite model provides robust support for OSAHS diagnosis and severity assessment. Twenty metabolites associated with OSAHS disease severity offer a new perspective for diagnosis.</p><p><strong>Citation: </strong>Wang X, Zhao J, Wang X, Zhang L. Metabolomic profiles predict clinical severity in patients with obstructive sleep apnea-hypopnea syndrome. <i>J Clin Sleep Med.</i> 2024;20(9):1445-1453.</p>\",\"PeriodicalId\":50233,\"journal\":{\"name\":\"Journal of Clinical Sleep Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11367723/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Sleep Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5664/jcsm.11160\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Sleep Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5664/jcsm.11160","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Metabolomic profiles predict clinical severity in patients with obstructive sleep apnea-hypopnea syndrome.
Study objectives: Obstructive sleep apnea-hypopnea syndrome (OSAHS) poses a significant health hazard, intermittent hypoxia inflicts damage throughout the body and is considered a critical risk factor for metabolic disorders. The aim of this study was to establish a metabolic profile for patients with OSAHS using nontargeted metabolomics detection techniques, providing a basis for OSAHS diagnosis and novel biological marker identification.
Methods: 45 patients with OSAHS composed the OSAHS group, and 44 healthy volunteers composed the control group. Nontargeted metabolomics technology was used to analyze participants' urinary metabolites. Differentially abundant metabolites were screened and correlated through hierarchical clustering analysis. We constructed a composite metabolite diagnostic model using a random forest model. Simultaneously, we analyzed the relationships between 20 metabolites involved in model construction and OSAHS severity.
Results: The urinary metabolomics pattern of the OSAHS group exhibited significant changes, demonstrating noticeable differences in metabolic products. Urinary metabolite analysis revealed differences between the mild-to-moderate OSAHS and severe OSAHS groups. The composite metabolite model constructed in this study demonstrated excellent diagnostic performance not only in distinguishing healthy control participants from patients with mild-to-moderate OSAHS (area under the curve = 0.78) and patients with severe OSAHS (area under the curve = 0.78), but also in discriminating between patients with mild-to-moderate and severe OSAHS (area under the curve = 0.71).
Conclusions: This study comprehensively analyzed the urinary metabolomic characteristics of patients with OSAHS. The established composite metabolite model provides robust support for OSAHS diagnosis and severity assessment. Twenty metabolites associated with OSAHS disease severity offer a new perspective for diagnosis.
Citation: Wang X, Zhao J, Wang X, Zhang L. Metabolomic profiles predict clinical severity in patients with obstructive sleep apnea-hypopnea syndrome. J Clin Sleep Med. 2024;20(9):1445-1453.
期刊介绍:
Journal of Clinical Sleep Medicine focuses on clinical sleep medicine. Its emphasis is publication of papers with direct applicability and/or relevance to the clinical practice of sleep medicine. This includes clinical trials, clinical reviews, clinical commentary and debate, medical economic/practice perspectives, case series and novel/interesting case reports. In addition, the journal will publish proceedings from conferences, workshops and symposia sponsored by the American Academy of Sleep Medicine or other organizations related to improving the practice of sleep medicine.